cr6086
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2017 (NCT03163966)
Timeline
Indications
Mechanism of action
- Prostanoid EP4 receptorINHIBITOR
PTGER4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cr6086
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05205330 | Phase 1/Phase 2 (Phase 2) | Nov 23, 2021 | Agenus Inc., IRCCS Istituto Nazionale dei Tumori, Rottapharm |
| NCT03163966 | Phase 2 | Sep 1, 2017 | Rottapharm |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rottapharm | For profit | 2 | 2 | 1 | 2017 |
| Agenus Inc. | For profit | 1 | 0 | 1 | 2021 |
| IRCCS Istituto Nazionale dei Tumori | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1